Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis

Related

• The American Journal of Cardiology·8 Oct 2026

  Drug class linked to fewer deaths or complications in kidney disease

  

• European Journal of Heart Failure·2 Oct 2026

  Proteomic multi-organ aging accelerates before adverse events in heart failure patients

  

• Diabetes, Obesity & Metabolism·4 Oct 2026

  GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

• Kidney Research and Clinical Practice·6 Oct 2026

  Blood protein links to heart attacks vary with kidney function